Charles River Laboratories International, Inc. has signed a multi-program agreement with Pioneering Medicines, a strategic initiative of Flagship Pioneering, to provide access to Logica, an artificial intelligence (AI) powered drug solution. Logica translates biological insights into optimized preclinical assets by leveraging Valo Health's AI-powered Opal Computational Platform and Charles River's leading preclinical expertise. Pioneering Medicines will deploy Logica across a portfolio of targets to create optimized small molecules that lead to novel therapies for unmet medical needs. The collaboration aims to accelerate the drug discovery process and deliver novel candidates to patients faster.
Logica is a uniquely integrated AI platform that draws on a wide breadth of tools to optimize drug discovery, coordinate laboratory infrastructure, expert drug hunters, and large-scale compute capabilities to eliminate whitespace and rapidly deliver results. Logica utilizes industry-leading predictive models, chemical design and synthesis capabilities, DNA-encoded libraries, in silico high throughput screening from Valo's Opal Computational Platform, as well as Charles River's leading capabilities in all aspects of discovery optimization, including high throughput screening, medicinal chemistry, ADME, biology, pharmacology, and ultimately safety testing and IND submission. It is offered as a fully managed, risk-sharing model, with most of the client cost tied to success.
With the combined power of Valo's Opal Computational Platform and Charles River's extensive drug discovery portfolio, Logica has the capability to transform a drug target into a first-in-class development candidate in just over two years. The collaboration with Pioneering Medicines aims to increase efficiency in drug discovery by more quickly advancing well-characterized molecules through the development process and creating and delivering novel medicines for patients sooner.
In 2022, Charles River and Valo Health, Inc. launched Logica, providing clients with transformed drug discovery with a single integrated offering seamlessly translating targets to candidate nomination. Logica is the result of the companies' collaboration to offer a computation-powered, unified target-to-candidate offering that combines industry-leading predictive models, chemical design and synthesis capabilities, DNA-encoded libraries, in silico high throughput screening, as well as Charles River's leading capabilities in all aspects of discovery optimization.
The Logica platform is expected to transform drug discovery by utilizing AI to accelerate and streamline the process, ultimately resulting in novel therapies for unmet medical needs. By leveraging Valo Health's Opal Computational Platform and Charles River's leading preclinical expertise, Logica offers a uniquely integrated solution to the drug discovery process. The fully managed, risk-sharing model and cost tied to success make it an attractive option for companies looking to develop novel therapies for patients. The collaboration with Pioneering Medicines is a step towards delivering optimized small molecules that lead to novel therapies for unmet medical needs.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!